JPH11507052A - キナゾリンおよび医薬組成物 - Google Patents

キナゾリンおよび医薬組成物

Info

Publication number
JPH11507052A
JPH11507052A JP9501345A JP50134597A JPH11507052A JP H11507052 A JPH11507052 A JP H11507052A JP 9501345 A JP9501345 A JP 9501345A JP 50134597 A JP50134597 A JP 50134597A JP H11507052 A JPH11507052 A JP H11507052A
Authority
JP
Japan
Prior art keywords
cells
disorders
cell
well
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP9501345A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11507052A5 (2
Inventor
タン，ぺン・チョー
マクマホン，ジェラルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of JPH11507052A publication Critical patent/JPH11507052A/ja
Publication of JPH11507052A5 publication Critical patent/JPH11507052A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP9501345A 1995-06-07 1996-06-04 キナゾリンおよび医薬組成物 Withdrawn JPH11507052A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48058995A 1995-06-07 1995-06-07
US08/480,589 1995-06-07
PCT/US1996/008877 WO1996040648A1 (en) 1995-06-07 1996-06-04 Quinazolines and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JPH11507052A true JPH11507052A (ja) 1999-06-22
JPH11507052A5 JPH11507052A5 (2) 2004-07-22

Family

ID=23908543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9501345A Withdrawn JPH11507052A (ja) 1995-06-07 1996-06-04 キナゾリンおよび医薬組成物

Country Status (7)

Country Link
US (1) US6103728A (2)
EP (1) EP0832073B1 (2)
JP (1) JPH11507052A (2)
AU (1) AU5984296A (2)
CA (1) CA2222545A1 (2)
DE (1) DE69618587T2 (2)
WO (1) WO1996040648A1 (2)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
TW321649B (2) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
EP0824525B1 (en) * 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
NZ510991A (en) 1997-03-05 2002-11-26 Sugen Inc Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
AU4317399A (en) 1998-05-28 1999-12-13 Parker Hughes Institute Quinazolines for treating brain tumor
US6800649B1 (en) 1998-06-30 2004-10-05 Parker Hughes Institute Method for inhibiting c-jun expression using JAK-3 inhibitors
EP1510212A1 (en) * 1998-08-21 2005-03-02 Parker Hughes Institute Use of 4-substituted-quinazoline derivatives for producing therapeutic agents
EP1105378B1 (en) 1998-08-21 2005-03-30 Parker Hughes Institute Quinazoline derivatives
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
US7064114B2 (en) 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
CN100376567C (zh) 1999-11-05 2008-03-26 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
US7160889B2 (en) 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
ATE360015T1 (de) * 2002-07-31 2007-05-15 Critical Outcome Technologies Protein tyrosin kinase inhibitoren
ATE380810T1 (de) * 2002-10-09 2007-12-15 Critical Outcome Technologies Protein-tyrosine-kinase-inhibitoren
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
JP2009504759A (ja) * 2005-08-16 2009-02-05 メモリ ファーマセチカル コーポレーション ホスホジエステラーゼ１０阻害剤
WO2007098169A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
AU2007221049A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
JP2010500365A (ja) * 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
CA2673683C (en) 2007-01-11 2014-07-29 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EA038195B1 (ru) 2009-01-16 2021-07-22 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
KR102061743B1 (ko) 2011-03-04 2020-01-03 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
FR3019819B1 (fr) * 2014-04-09 2018-03-23 Centre National De La Recherche Scientifique (Cnrs) Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
BR112020022738A2 (pt) 2018-05-18 2021-02-02 Novartis Ag formas cristalinas de um inibidor tlr7/tlr8

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36256A (en) * 1862-08-19 Improvement in sewing-m ach ines
US3266990A (en) * 1963-09-24 1966-08-16 Warner Lambert Pharmaceutical Derivatives of quinazoline
US3800039A (en) * 1970-10-21 1974-03-26 Mead Johnson & Co Antithrombogenic process employing substituted 6,7-dialkoxyquinazolines
US4343940A (en) * 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
EP0031237B1 (en) * 1979-12-19 1984-10-17 National Research Development Corporation Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4966849A (en) * 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
DE3611194A1 (de) * 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
IL89027A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
DE3920029C2 (de) * 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Farbstoffe zum Färben von Kunststoffen
WO1991015495A1 (en) * 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
CA2102780C (en) * 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2108889A1 (en) * 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9205320D0 (en) * 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
CA2140440A1 (en) * 1992-08-06 1994-02-17 Ellen M. Dobrusin 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
DK1975181T3 (da) * 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity

Also Published As

Publication number Publication date
EP0832073A1 (en) 1998-04-01
AU5984296A (en) 1996-12-30
EP0832073B1 (en) 2002-01-16
WO1996040648A1 (en) 1996-12-19
DE69618587T2 (de) 2002-08-29
US6103728A (en) 2000-08-15
DE69618587D1 (de) 2002-02-21
CA2222545A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
US5650415A (en) Quinoline compounds
US5773459A (en) Urea- and thiourea-type compounds
US5710173A (en) Thienyl compounds for inhibition of cell proliferative disorders
EP0832073B1 (en) Quinazolines and pharmaceutical compositions
US5891917A (en) Certain acrylonitrile-sulfonamide derivatives
EP0748219B1 (en) Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5849742A (en) Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) Quinazoline compounds and compositions thereof for the treatment of disease
US6225346B1 (en) Tyrphostin like compounds
US5763441A (en) Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5981569A (en) Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5880141A (en) Benzylidene-Z-indoline compounds for the treatment of disease
US5763470A (en) Benzopyran compounds and methods for their use
DE69734521T9 (de) Kombinatorische indolinonbibliotheken und verwandte produkte und verfahren zur behandlung von erkrankungen
US20020068687A1 (en) Methods and compositions for inhibiting cell proliferative disorders
WO1998024432A2 (en) Use of indolinone compounds as modulators of protein kinases
US6649635B2 (en) Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
WO1997034920A1 (en) Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
CA2302438A1 (en) Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
HK1012559B (en) Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060602